GlassScriptPhysician profile
Jason M Loden
NPI 1710327879
$21,886.30
in general payments reported to CMS, 2019-2025
21 companies · $18.63 in 2025
The $18.63 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $150 · 2021: $141 · 2022: $27.39 · 2023: $12K · 2024: $9,283 · 2025: $18.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $18K · Food and Beverage: $2,164 · Travel and Lodging: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $17,500.00 |
| Food and Beverage | $2,164.16 |
| Travel and Lodging | $1,664.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $20,615.62 | 2023-2024 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Davol INC. | $333.47 | 2019-2023 | Phasix Mesh |
| Boston Scientific Corporation | $193.40 | 2023-2025 | Spyglass Discover |
| Ethicon US, LLC | $181.97 | 2024 | Echelon Flex |
| Amgen INC. | $107.77 | 2019-2022 | |
| Polynovo North America LLC | $77.20 | 2024 | Novosorb Btm |
| Abiomed | $58.35 | 2021 | |
| Abbvie INC. | $42.00 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $40.11 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.84 | 2021 | |
| Organogenesis INC. | $33.89 | 2021-2022 | |
| Kerecis Limited | $27.05 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Becton, Dickinson and Company | $21.08 | 2024 | Phasix Mesh |
| Kci USA, INC. | $20.39 | 2023 | V.A.C. Veraflo, Prevena, V.A.C. Veraflo Cleanse Choice |
| Tela Bio, INC. | $17.11 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $16.33 | 2019 | |
| Grifols USA, LLC | $14.75 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.92 | 2023 | Gattex |
| Novo Nordisk INC | $12.19 | 2020 | |
| Dexcom, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Loden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.